Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 20/20 | 0.98 |
| ▸ | TRPV4 | Q9HBA0 | 12/20 | 0.98 |
| ▸ | TRPV3 | Q8NET8 | 4/20 | 0.98 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474789 | 0.99 | TRPA1 (1.00) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL30167897 | 0.99 | TRPA1 (1.00) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL18813640 | 0.98 | TRPA1 (0.98) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL474659 | 0.98 | TRPA1 (0.98) | TRPA1TRPV4TRPV3TRPV1 | |
| Potassium SCHEMBL16653276 | 0.98 | TRPA1 (0.98) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL16663485 | 0.93 | TRPA1 (0.88) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL14227824 | 0.92 | TRPA1 (0.86) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL15158331 | 0.91 | TRPA1 (0.85) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL15241213 | 0.89 | TRPA1 (0.82) | TRPA1TRPV4TRPV3TRPV1 | |
| SCHEMBL474848 | 0.89 | TRPA1 (0.81) | TRPA1TRPV4TRPV3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532988-B2 | Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-03 | — | — | US | claimed |
| EP-2858999-B1 | AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS | GLENMARK PHARMACEUTICALS SA (CH) | 2017-05-10 | — | — | EP | disclosed |
| US-9458173-B2 | Amides of 2-amino-4-arylthiazole compounds and their salts | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-10-04 | — | — | US | disclosed |
| US-20150111038-A1 | AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111038-A1 | AMIDES OF 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AND THEIR SALTS | AADAC, ABL2, ABL1 | TRPA1 518/4885TRPV4 828/4885TRPV3 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.